Loading
Separate from patents, US law gives an approved drug fixed periods during which the FDA will not approve a copy: five years for a new chemical, three for new clinical studies, seven for an orphan indication, twelve for a biologic, plus six months for paediatric studies.
United States, federal statutes read together. Regulatory exclusivity is granted by the FDA under several statutes: five years of new chemical entity exclusivity and three years of new clinical investigation exclusivity under Hatch-Waxman (1984); seven years of orphan exclusivity under the Orphan Drug Act (1983); twelve years for a reference biologic under the BPCIA (2010); six months of paediatric exclusivity added to all of the above under BPCA (2002); and 180 days of generic exclusivity for the first successful patent challenger. Primary text: the FDA's patents and exclusivity FAQ lists each with its statutory citation.
How it works: exclusivity runs from approval and does not depend on having a patent, so it matters most for drugs whose patents are weak or expire early, and for biologics where patents are hard to design around. Patents and exclusivity run in parallel; the later date controls when a generic or biosimilar can launch, which is the logic behind the exclusivity timeline on this site. Orphan exclusivity blocks only the same drug for the same indication, and a company can stack orphan indications to extend protection.
The arguments: the twelve-year biologic term is the longest in the world and the Obama and Trump administrations both proposed cutting it; small-molecule sponsors argue the five-year term is short and that the Inflation Reduction Act's earlier negotiation clock for pills compounds the gap. The European Union's 8+2+1 system and Japan's re-examination period are the comparators.
Shares TRIPS Agreement and the Doha Declaration, Nexavar compulsory licence (India, 2012) and the tags law, us.
Shares Inflation Reduction Act 2022: Medicare drug price negotiation, Prices and value and the tags law, us.
Shares Paediatric drug laws: BPCA and PREA and the tags law, us.
Shares Incentives reward me-too drugs and marginal gains and the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Shares the tags law, us.
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/